Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 18
2014 41
2015 56
2016 89
2017 98
2018 158
2019 358
2020 564
2021 618
2022 558
2023 473
2024 190

Text availability

Article attribute

Article type

Publication date

Search Results

3,220 results

Results by year

Filters applied: . Clear all
Page 1
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, Yeo ECF, Wittwer NL, Tapia Rico G, Logan J, Sivaloganathan P, Collis M, Ruszkiewicz A, Brown MP. Gargett T, et al. J Immunother Cancer. 2024 May 15;12(5):e008659. doi: 10.1136/jitc-2023-008659. J Immunother Cancer. 2024. PMID: 38754916 Free PMC article. Clinical Trial.
Therapeutic Inducers of Natural Killer cell Killing (ThINKK): preclinical assessment of safety and efficacy in allogeneic hematopoietic stem cell transplant settings.
Poirier N, Paquin V, Leclerc S, Lisi V, Marmolejo C, Affia H, Cordeiro P, Théorêt Y, Haddad E, Andelfinger G, Lavallée VP, Duval M, Herblot S. Poirier N, et al. J Immunother Cancer. 2024 May 15;12(5):e008435. doi: 10.1136/jitc-2023-008435. J Immunother Cancer. 2024. PMID: 38754915 Free PMC article.
Stealth transgenes enable CAR-T cells to evade host immune responses.
Grauwet K, Berger T, Kann MC, Silva H, Larson R, Leick MB, Bailey SR, Bouffard AA, Millar D, Gallagher K, Turtle CJ, Frigault MJ, Maus MV. Grauwet K, et al. J Immunother Cancer. 2024 May 9;12(5):e008417. doi: 10.1136/jitc-2023-008417. J Immunother Cancer. 2024. PMID: 38724463 Free PMC article.
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, Retzlaff J, Dörrie J, Schaft N, Wiesinger M, März J, Schuler-Thurner B, Knorr H, Gupta S, Singh KP, Schuler G, Heppt MV, Koch EAT, van Kleef ND, Freen-van Heeren JJ, Turksma AW, Wolkenhauer O, Hohberger B, Berking C, Bruns H, Vera J. Lischer C, et al. J Immunother Cancer. 2024 May 9;12(5):e008104. doi: 10.1136/jitc-2023-008104. J Immunother Cancer. 2024. PMID: 38724462 Free PMC article.
3,220 results